Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5:29:100995.
doi: 10.1016/j.conctc.2022.100995. eCollection 2022 Oct.

Acceptability and feasibility of fecal microBIOME and serum metabolite sample collection in people with end-stage kidney disease and pain being treated with HemoDialysis: A pilot study (BIOME-HDp)

Mark B Lockwood  1 , Michael J Fischer  2 , Kimberly Silva  3 , Blanca N Contreras  3 , Guillermo Zamora  3 , Amanda Goldstein  3 , Monya Meinel  3 , Christopher Holden  4 , James Lash  5 , Alana Steffens  6 , Ardith Doorenbos  7
Affiliations

Acceptability and feasibility of fecal microBIOME and serum metabolite sample collection in people with end-stage kidney disease and pain being treated with HemoDialysis: A pilot study (BIOME-HDp)

Mark B Lockwood et al. Contemp Clin Trials Commun. .

Abstract

Pain is known to reduce hemodialysis treatment adherence, reduce quality of life, and increase mortality. The absence of effective strategies to treat pain without medications has contributed to poor health outcomes for people with end-stage kidney disease (ESKD) on hemodialysis. It is now recognized that symbiotic microbiota in the gut play a critical role in health and disease, and new evidence sheds light on the role of the microbiome in chronic pain. The pilot study protocol presented here (BIOME-HDp) employs a longitudinal repeated measures design to interrogate the effects of a nonpharmacological pain intervention on the composition and function of the gut microbiome and circulating metabolites. This pilot study is an ancillary study of the HOPE Consortium Trial to reduce pain and opioid use in hemodialysis, which is part of the NIH's Helping to End Addiction Long-term (HEAL) initiative. The BIOME-HDp pilot study will establish clinical microbiome research methods and determine the acceptability and feasibility of fecal microbiome and serum metabolite sample collection.

Keywords: End-stage kidney disease; Gut microbiome; Metabolomics; Pain; Symptom science.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Timeline of events for the Biome-HDp pilot study.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kimmel P.L., Cohen S.D., Weisbord S.D. Quality of life in patients with end-stage renal disease treated with hemodialysis: survival is not enough. J. Nephrol. 2008;21(Suppl 13):S54–S58. - PubMed
    1. Davison S.N. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am. J. Kidney Dis. 2003;42(6):1239–1247. - PubMed
    1. Kimmel P.L., Fwu C.-W., Abbott K.C., Eggers A.W., Kline P.P., Eggers P.W. Opioid prescription, morbidity, and mortality in United States dialysis patients. J. Am. Soc. Nephrol. 2017;28(12):3658–3670. - PMC - PubMed
    1. Wyne A., Rai R., Cuerden M., Clark W.F., Suri R.S. Opioid and benzodiazepine use in end-stage renal disease: a systematic review. Clin. J. Am. Soc. Nephrol. : CJASN. 2011;6(2):326–333. - PMC - PubMed
    1. Dolati S., Tarighat F., Pashazadeh F., Shahsavarinia K., Gholipouri S., Soleimanpour H. The role of opioids in pain management in elderly patients with chronic kidney disease: a review article. Anesthesiol. Pain Med. 2020;10(5) - PMC - PubMed

LinkOut - more resources